natgillin/translations-raw huggingface dataset:
• shortness of breath
• kratka sapa
You may also experience breakdown of muscle, muscle pain or weakness, softening of the bones (with bone pain and sometimes resulting in fractures), fatty liver, inflammation of the kidney, passing a lot of urine and feeling thirsty.
Lahko se pojavijo tudi razpad mišičnega tkiva, bolečine v mišicah ali mišična oslabelost, mehčanje kosti (z bolečinami v kosteh, včasih tudi zlom), zamaščena jetra, vnetje ledvic, izločanje večjih količin urina in občutek žeje.
Tests may also show decreases in potassium in the blood.
Preiskave lahko pokažejo tudi zmanjšanje količine kalija v krvi.
29 The breakdown of muscle, softening of the bones (with bone pain and sometimes resulting in fractures), muscle pain, muscle weakness and decreases in potassium or phosphate in the blood may occur due to damage to kidney tubule cells.
29 Razpad mišičnega tkiva, mehčanje kosti (z bolečinami v kosteh, včasih tude zlom), bolečine v mišicah, mišična oslabelost in zmanjšanje količine kalija ali fosfatov v krvi se lahko pojavi zaradi okvare celic ledvičnih tubulov.
Children who were administered emtricitabine, one of the components of Truvada, also experienced anaemia (low red blood cell count), commonly and changes in skin colour including darkening of the skin in patches, very commonly.
Pri otrocih, ki so jemali emtricitabin, eno od učinkovin zdravila Truvada, je bila pogosta tudi anemija (nizko število rdečih krvnih telesc) in zelo pogosta sprememba obarvanosti kože, vključujoč temne lise.
Combination antiretroviral therapy (such as Truvada) may change your body shape, by changing the way body fat is distributed.
Kombinirana protiretrovirusna terapija (kot je zdravilo Truvada) lahko povzroči spremembe telesne oblike zaradi sprememb v razporeditvi maščob.
You may lose fat from your legs, arms and face; gain fat around the abdomen (tummy) and internal organs; get larger breasts or fatty lumps on the back of the neck (‘buffalo hump’).
Izgubite lahko maščevje na nogah, rokah in obrazu; pridobite maščevje na trebuhu in notranjih organih; lahko se vam povečajo prsi ali maščobna bula na tilniku (“ bivolja grba ”).
HOW TO STORE TRUVADA
SHRANJEVANJE ZDRAVILA TRUVADA
Do not use Truvada after the expiry date which is stated on the bottle and carton after {EXP}.
Zdravila Truvada ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na plastenki in škatli poleg oznake {EXP}.
What Truvada contains
Kaj vsebuje zdravilo Truvada
• The active substances are emtricitabine and tenofovir disoproxil.
• Zdravilni učinkovini sta emtricitabin in tenofovirdizoproksilat.
Each Truvada film-coated tablet contains 200 mg of emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300 mg of tenofovir disoproxil fumarate, or 136 mg of tenofovir).
Ena filmsko obložena tableta Truvade vsebuje 200 mg emtricitabina in 245 mg tenofovirdizoproksilata (kar je ekvivalentno 300 mg tenofovirdizoproksil fumarata ali 136 mg tenofovirja).
• The other ingredients are croscarmellose sodium, glycerol triacetate (E1518), hypromellose (E464), indigo carmine aluminium lake (E132), lactose monohydrate, magnesium stearate (E572), microcrystalline cellulose (E460), pregelatinised starch (gluten free) and titanium dioxide (E171).
• Pomožne snovi so premreženi natrijev karmelozat, triacetin (E1518), hipromeloza (E464), barvilo indigo karmin (E132), laktoza monohidrat, magnezijev stearat (E572), mikrokristalna celuloza (E460), predgelirani škrob (brez glutena) in titanov dioksid (E171).
Truvada film-coated tablets are blue, capsule-shaped tablets, engraved on one side with the word “GILEAD” and on the other side with the number “701”.
Truvada filmsko obložene tablete so modre tablete kapsulne oblike z vtisnjeno besedo “ GILEAD ” na eni strani in številko “ 701 ” na drugi strani.
30 Marketing Authorisation Holder and Manufacturer:
30 Imetnik dovoljenja za promet z zdravilom in izdelovalec
It contains inactivated (killed) hepatitis A viruses and parts of the hepatitis B virus as active substances.
Zdravilo kot zdravilno učinkovino vsebuje inaktivirane (mrtve) viruse hepatitisa A in dele virusa hepatitisa B.
It is available in a 1 ml vial and in a 1 ml prefilled syringe.
Na voljo je v obliki 1 ml vial in 1 ml napolnjenih injekcijskih brizg.
Twinrix Adult contains small amounts of inactivated hepatitis A viruses and the ‘ surface antigen ’ (proteins from the surface) of the hepatitis B virus.
Zdravilo Twinrix Adult vsebuje majhne količine inaktiviranih virusov hepatitisa A in „ površinskih antigenov “ (beljakovin iz površine) virusa hepatitisa B.
When a person is given the vaccine, the immune system recognises the viruses and surface antigens as ‘ foreign’ and makes antibodies against them.
Kadar oseba prejme cepivo, imunski sistem prepozna viruse in površinske antigene kot „ tuje “ ter začne proti njim tvoriti protitelesa.
Reproduction is authorised provided the source is acknowledged. by a method known as ‘ recombinant DNA technology’: they are made by a yeast that has received a gene (DNA), which makes it able to produce the proteins.
To pomeni, da so virusi in površinski antigeni vezani na aluminijeve spojine, da bi spodbudili boljši odziv.
The active substances in Twinrix Adult have been available in the European Union (EU) for a number of years in separate vaccines:
Zdravilne učinkovine cepiva Twinrix Adult so v Evropski uniji (EU) na voljo že mnoga leta kot samostojna cepiva:
Havrix Adult for protection against hepatitis A and Engerix-B for protection against hepatitis B.
Havrix Adult za zaščito proti virusu hepatitisa A in Engerix- B za zaščito proti virusu hepatitisa B.
The studies showed that for hepatitis A, antibodies were detected in 94% of adults after the first dose, 99.5% after the second dose and 100% after the third dose.
Študije so pokazale, da so protitelesa proti hepatitisu A opazili pri 94% odraslih po prvem odmerku, pri 99, 5% po drugem odmerku in pri 100% po tretjem odmerku.
For hepatitis B, antibodies were detected in 71% of adults after the first dose, 97% after the second dose and 99.7% after the third dose.
Protitelesa proti hepatitisu B so opazili pri 71% odraslih po prvem odmerku, pri 97% po drugem odmerku in pri 99, 7% po tretjem odmerku.
The three-week vaccination schedule also led to the production of antibodies in around 83% of patients, rising to around 89% after the booster dose at month 12.
Tri tedne trajajoče cepljenje je prav tako privedlo do tvorjenja protiteles pri približno 83% bolnikov, ta delež pa se je po poživitvenem odmerku v 12. mesecu povzpel na približno 89%.
The Committee for Medicinal Products for Human Use (CHMP) decided that Twinrix Adult’ s benefits are greater than its risks for use in non-immune adults and adolescents of 16 years of age and above who are at risk of both hepatitis A and hepatitis B infection.
Odbor za zdravila za uporabo v humani medicini (CHMP) je odločil, da so koristi zdravila Twinrix Adult pri uporabi pri neimunih odraslih in mladostnikih, starih 16 let ali več, pri katerih obstaja tveganje okužbe s hepatitisom A in hepatitisom B, večje od z njim povezanih tveganj.
The European Commission granted a marketing authorisation valid throughout the EU to GlaxoSmithKline Biologicals s. a. for Twinrix Adult on 20 September 1996.
Evropska komisija je dovoljenje za promet z zdravilom Twinrix Adult, veljavno po vsej Evropski uniji, odobrila družbi GlaxoSmithKline Biologicals s. a. dne 20. septembra 1996.
Twinrix Adult, suspension for injection Hepatitis A (inactivated) and hepatitis B(rDNA) (HAB) vaccine (adsorbed).
Twinrix za odrasle, suspenzija za injiciranje Cepivo proti hepatitisu A, inaktivirano, in hepatitisu B, rekombinantno (HAB), adsorbirano
Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology 4 Adsorbed on aluminium phosphate
0, 05 miligrama Al3+ Adsorbiran na hidratirani aluminijev hidroksid 3 Pridobljen s tehnologijo rekombinantne DNA na celični kulturi kvasovk (Saccharomyces cerevisiae) 4 0, 4 miligrama Al3+ Adsorbiran na aluminijev fosfat
Turbid white suspension.
Suspenzija za injiciranje Motna bela suspenzija
A dose of 1.0 ml is recommended for adults and adolescents 16 years of age and above.
Za odrasle in mladostnike, stare 16 let in več, je priporočljiv odmerek 1, 0 ml.
Long-term antibody persistence data following vaccination with TWINRIX Adult are available up to 60 months after vaccination.
Na voljo so podatki o dolgotrajni prisotnosti protiteles po cepljenju s cepivom Twinrix za odrasle v trajanju do 60 mesecev po cepljenju.
The anti-HBs and anti-HAV antibody titres observed following a primary vaccination course with the combined vaccine are in the range of what is seen following vaccination with the monovalent vaccines.
Titri anti- HBs in anti- HAV protiteles, opaženi po osnovnem cepljenju, so primerljivi z opažanji po cepljenju z monovalentnimi cepivi.
The need for a booster dose of hepatitis B vaccine in healthy individuals who have received a full primary vaccination course has not been established; however some official vaccination programmes currently include a recommendation for a booster dose of hepatitis B vaccine and these should be respected.
Kljub temu nekateri uradni programi cepljenja vsebujejo priporočilo za poživitveno cepljenje s cepivom proti hepatitisu B in ta priporočila je potrebno upoštevati.
For some categories of subjects or patients exposed to HBV (e. g; haemodialysis or immunocompromised patients) a precautionary attitude should be considered to ensure a protective antibody level ≥ 10IU/ l.
Pri nekaterih kategorijah oseb ali bolnikov, izpostavljenih HBV (npr. bolniki na hemodializi ali imunsko pomanjkljive osebe), je zaradi zagotovitve zaščitnega nivoja protiteles ≥ 10 i. e. / l potrebna posebna previdnost.
Guidelines for boosting are based on the assumption that antibodies are required for protection; anti-HAV antibodies have been predicted to persist for at least 10 years.
Smernice za poživitveno cepljenje temeljijo na predpostavki, da so za zaščito nujno potrebna protitelesa; anti- HAV protitelesa naj bi se po ocenah ohranila najmanj 10 let.
(see section 4.4).
Vsekakor pa se lahko zaradi tega pričakuje pomanjkljiv imunski odgovor na cepljenje (glejte poglavje 4. 4).
It is possible that subjects may be in the incubation period of a hepatitis A or hepatitis B infection at the time of vaccination.
4. 4 Posebna opozorila in previdnostni ukrepi
It is not known whether Twinrix Adult will prevent hepatitis A and hepatitis B in such cases.
Ni znano, če Twinrix za odrasle v teh primerih prepreči bolezni.
3 Twinrix Adult is not recommended for postexposure prophylaxis (e. g. needle stick injury).
3 Cepivo ni bilo preizkušeno pri bolnikih z oslabljeno imunostjo.
In haemodialysis patients and persons with an impaired immune system, adequate anti-HAV and anti-HBs antibody titers may not be obtained after the primary immunisation course and such patients may therefore require administration of additional doses of vaccine.
Pri bolnikih na hemodializi in osebah s slabšim imunskim odzivom po osnovnem cepljenju morda ne bo dosežen ustrezen titer protiteles anti - HAV in anti- HBs, zato bodo tovrstni bolniki morda potrebovali dodatne odmerke cepiva.
Obesity (defined as BMI ≥ 30 kg/ m2) has been observed to reduce the immune response to hepatitis A vaccines.
Ugotovljeno je bilo, da prekomerna telesna masa (definirana z indeksom telesne mase (ITM) ≥ 30 kg/ m2) zmanjša imunski odziv na cepiva proti hepatitisu A.
A number of factors have been observed to reduce the immune response to hepatitis B vaccines.
Ugotovljeni so bili še številni drugi dejavniki, ki vplivajo na slabši imunski odziv po cepljenju s cepivi proti hepatitisu B.
These factors include older age, male gender, obesity, smoking, route of administration, and some chronic underlying diseases.
To so: višja starost, moški spol, debelost, kajenje, način dajanja cepiva ali nekatere obstoječe kronične bolezni.
However, exceptionally Twinrix Adult can be administered subcutaneously to subjects with thrombocytopenia or bleeding disorders since bleeding may occur following an intramuscular administration to these subjects (see section 4.2.).
Izjemoma se Twinrix za odrasle lahko daje subkutano in sicer bolnikom s trombocitopenijo in bolnikom z motnjami strjevanja krvi, ker lahko pri njih po intramuskularnem injiciranju nastopi krvavitev (glejte poglavje 4. 2).
TWINRIX ADULT SHOULD UNDER NO CIRCUMSTANCES BE ADMINISTERED INTRAVASCULARLY.
CEPIVA TWINRIX ZA ODRASLE SE V NOBENEM PRIMERU NE SME DAJATI V ŽILO.
As with any vaccine, a protective immune response may not be elicited in all vaccinees.
Kot cepljenje s katerimkoli cepivom lahko tudi cepljenje s cepivom Twinrix za odrasle ne izzove zaščitnega imunskega odgovora pri vseh cepljenih osebah.
As with any injection procedure, vasovagal syncope can infrequently occur following administration of Twinrix Adult to adults and adolescents.
Kot pri vsakem injiciranju, lahko pri odraslih ali mladostnikih po cepljenju z cepivom Twinrix za odrasle redko pride do vazovagalne sinkope.
No data on concomitant administration of Twinrix Adult with specific hepatitis A immunoglobulin or hepatitis B immunoglobulin have been generated.
Ni zbranih podatkov o sočasnem dajanju cepiva Twinrix za odrasle in specifičnih imunoglobulinov proti hepatitisu A ali hepatitisu B.
However, when the monovalent hepatitis A and hepatitis B vaccines were administered concomitantly with specific immunoglobulins, no influence on seroconversion was observed although it may result in lower antibody titres.
Vsekakor pa, kadar sta bili monovalentni cepivi proti hepatitisu A ali hepatitisu B dani hkrati s specifičnimi imunoglobulini, ni bilo opaziti vpliva na serokonverzijo, čeprav so titri protiteles lahko nižji.
This study did not indicate direct or indirect harmful effects with respect to fertility, pregnancy, embryonal/ fetal development, parturition or post-natal development.
Ta študija ni pokazala neposrednih ali posrednih škodljivih vplivov na plodnost, brejost, razvoj zarodka/ plodu, porod ali postnatalni razvoj.
4 Data on outcomes of a limited number of pregnancies in vaccinated women do not indicate any adverse effects of Twinrix Adult on pregnancy or on the health of the fetus/ newborn child.
Podatki o izidih nosečnosti, pridobljeni pri manjšem številu cepljenih nosečnic, ne kažejo na možnost škodljivih vplivov cepiva Twinrix za odrasle na nosečnost ali zdravje plodu/ novorojenca.
It is unknown whether Twinrix Adult is excreted in human breast milk.
4 Dojenje
The excretion of Twinrix Adult in milk has not been studied in animals.
Ni znano, če se cepivo Twinrix za odrasle izloča v materino mleko.
A decision on whether to continue/ discontinue breast- feeding or to continue/ discontinue therapy with Twinrix Adult should be made taking into account the benefit of breast-feeding to the child and the benefit of Twinrix Adult therapy to the woman.
Pri odločanju o nadaljevanju/ prekinitvi dojenja ali nadaljevanju/ prekinitvi cepljenja s cepivom Twinrix za odrasle je treba upoštevati tako korist dojenja za otroka kot korist cepljenja s cepivom Twinrix za odrasle za mater.
The current formulation of Twinrix does not contain thiomersal (an organomercuric compound) or any preservative.
Sedanja formulacija cepiva Twinrix ne vsebuje tiomersala (organske živosrebrove spojine) ali katerega koli drugega konzervansa.
In a clinical study conducted with the current formulation, the incidence of pain, redness, swelling, fatigue, gastro-enteritis, headache and fever was comparable to the incidence observed with the former thiomersal and preservative containing vaccine formulation.
Pri klinični študiji, izvedeni s sedanjo formulacijo cepiva, je bila pojavnost bolečine, rdečine, otekline, utrujenosti, gastroenteritisa, glavobola in zvišane telesne temperature primerljiva s pojavnostjo pri prejšnji formulaciji cepiva, ki je vsebovala tiomersal in konzervans.
The following undesirable effects have been reported following the widespread use of the former formulation.
V nadaljevanju so navedeni neželeni učinki, o katerih so poročali pri množični uporabi prejšnje formulacije cepiva.
The safety profile presented below is based on a pooled analysis of events per dose from more than 6,000 subjects who received either the standard 0, 1, 6 month schedule (n=5,683) or the accelerated 0, 7, 21 days schedule (n=320).
Prikazan varnostni profil je osnovan na skupni analizi dogodkov na odmerek pri več kot 6. 000 osebah, ki so bile cepljene po standarni shemi (0, 1, 6 mesec) (n=5, 683) ali pospešeni shemi (0, 7, 21 dan) cepljenja (n=320).
Frequencies are reported as:
Zelo redki:
Very common: ≥ 1/ 10 Common:
< 1/ 10. 000
* refers to adverse reactions observed in clinical trials performed with the paediatric formulation
* se nanaša na splošne reakcije, ki se lahko pojavijo v kliničnih preskusih z cepivom za otroke
Blood and lymphatic system disorders Rare: lymphadenopathy
Bolezni krvi in limfatičnega sistema Redki: limfadenopatija
Nervous system disorders Very common: headache Uncommon: dizziness Rare: hypoaesthesia, paraesthesia
Bolezni živčevja Zelo pogosti: glavobol Občasni: omotica Redki: hipestezija, parestezija
Gastrointestinal disorders
Bolezni prebavil Pogosti: gastrointestinalni simptomi, driska, navzea Občasni: bruhanje, bolečine v trebuhu *
5 Common: gastrointestinal symptoms, diarrhoea, nausea Uncommon: vomiting, abdominal pain*
5 Bolezni kože in podkožja Redki: izpuščaj, srbenje Zelo redki: koprivnica
Skin and subcutaneous tissue disorders Rare: rash, pruritus Very rare: urticaria
Mišičnoskeletni sistem in vezivno tkivo Občasni: mialgija Redki: artralgija
Metabolism and nutrition disorders Rare: decreased appetite
Presnovne in prehranske motnje Redki: zmanjšan apetit
Infections and infestations Uncommon: upper respiratory tract infection
Infekcije in parazitske bolezni Občasni: okužba zgornjih dihalnih poti
Vascular disorders Rare: hypotension
Žilne bolezni Redki: hipertenzija
General disorders and administration site conditions Very common: pain and redness at the injection site, fatigue Common: swelling at the injection site, injection site reactions (such as haematoma, pruritus and bruising), malaise Uncommon: fever (≥ 37.5°C) Rare: influenza like illness, chills
Splošne težave in spremembe na mestu aplikacije Zelo pogosti: bolečina in rdečina na mestu injiciranja, utrujenost Pogosti: oteklina na mestu injiciranja, reakcije na mestu injiciranja (kot so hematom, srbenje in pojav modric), občutek slabosti Občasni: zvišana telesna temperatura (≥ 37, 5°C) Redki: gripi podobni simptomi, utrujenost
Blood and lymphatic system disorders Thrombocytopenia, thrombocytopenic purpura
Bolezni krvi in limfatičnega sistema Trombocitopenija, trombocitopenična purpura
Nervous system disorders Encephalitis, encephalopathy, neuritis, neuropathy, paralysis, convulsions
Bolezni živčevja Encefalitis, encefalopatija, nevritis, nevropatija, paraliza, konvulzije
Skin and subcutaneous tissue disorders Angioneurotic oedema, lichen planus, erythema multiforme
Bolezni kože in podkožja Angionevrotični edem, lihen planus, multiformni eritem
Musculoskeletal and connective tissue disorders Arthritis, muscular weakness
Mišičnoskeletni sistem in vezivno tkivo Artritis, mišična slabost
Infections and infestations Meningitis
Infekcije in parazitske bolezni Meningitis
Vascular disorders Vasculitis
Žilne bolezni Vaskulitis
Immune system disorders Anaphylaxis, allergic reactions including anaphylactoid reactions and mimicking serum sickness
Bolezni imunskega sistema Anafilaksijske, alergijske reakcije vključno z anafilaktoidnimi reakcijami in serumski bolezni podobno stanje
Following widespread use of the monovalent hepatitis A and/ or hepatitis B vaccines, the following undesirable events have additionally been reported in temporal association with vaccination.
Pri spremljanju množične uporabe monovalentnih cepiv proti hepatitisu A in/ ali hepatitisu B so dodatno poročali o naslednjih neželenih učinkih, ki so bili časovno povezani s cepljenjem.
Investigations
Preiskave Nenormalne vrednosti preiskav jetrne funkcije
6 Abnormal liver function tests
6 Bolezni živčevja Multipla skleroza, mielitis, ohromelost obraza, polinevritis, kot je Guillain- Barréjev sindrom (z ascendentno paralizo), optični nevritis
Twinrix Adult confers immunity against HAV and HBV infection by inducing specific anti-HAV and anti-HBs antibodies.
Twinrix za odrasle omogoča imunost proti virusom hepatitisa A in hepatitisa B z indukcijo specifičnih anti- HAV in anti- HBs protiteles.
Protection against hepatitis A and hepatitis B develops within 2-4 weeks.
Zaščita pred virusom hepatitisa A in hepatitisa B se razvije v 2- 4 tednih.
In the clinical studies, specific humoral antibodies against hepatitis A were observed in approximately 94% of the adults one month after the first dose and in 100% one month after the third dose (i. e. month 7).
V kliničnih študijah so specifična humoralna protitelesa proti hepatitisu A ugotovili pri približno 94% odraslih oseb en mesec po aplikaciji prvega odmerka cepiva in pri 100% oseb en mesec po aplikaciji tretjega odmerka (to je mesec 7).
Specific humoral antibodies against hepatitis B were observed in 70% of the adults after the first dose and approximately 99% after the third dose.
Specifična humoralna protitelesa proti hepatitisu B so ugotovili pri 70% odraslih po prvem odmerku in pri približno 99% po tretjem odmerku.
The 0, 7 and 21 day primary schedule plus a fourth dose at month 12 is for use in exceptional circumstances in adults.
V izjemnih okoliščinah se pri odraslih lahko uporabi osnovno shemo cepljenja (0, 7. in 21. dan) z dodatnim četrtim odmerkom 12 mesecev po prvem odmerku.
In a clinical trial where Twinrix Adult was administered according to this schedule, 82% and 85% of vaccinees had seroprotective levels of anti-HBV antibodies at 1 and 5 weeks respectively following the third dose (i. e. at months 1 and 2 after the initial dose).
V klinični raziskavi so uporabili to shemo cepljenja in ugotovili, da je imelo 82% cepljenih oseb zaščitni nivo anti- HBV protiteles v 1. tednu in 85% cepljenih oseb v 5. tednu po aplikaciji tretjega odmerka (to je en in dva meseca po prvem odmerku).
The seroprotection rate against hepatitis B increased to 95.1% by three months after the first dose.
Stopnja zaščite proti hepatitisu B je porasla na 95, 1% v treh mesecih po prvem odmerku.
Seropositivity rates for anti-HAV antibodies were 100%, 99.5% and 100% at months 1, 2 and 3 after the initial dose.
Stopnja seropozitivnosti za anti- HAV protitelesa je bila 100% en mesec, 99, 5% dva meseca in 100% tri mesece po prvem odmerku.
One month after the fourth dose, all vaccinees demonstrated seroprotective levels of anti-HBs antibodies and were seropositive for anti-HAV antibodies.
En mesec po četrtem odmerku so imele vse cepljene osebe zaščitni nivo anti- HBs protiteles in so bile seropozitivne na anti- HAV protitelesa.
In a clinical study conducted in subjects over 40 years of age, the seropositivity rate for anti-HAV antibodies and seroprotection rate against hepatitis B of Twinrix Adult following a 0, 1, 6 months schedule were compared with the seropositivity and seroprotection rates of monovalent hepatitis A and B vaccines when administered in opposite arms.
V klinični študiji pri osebah, starejših od 40 let, so primerjali stopnjo seropozitivnosti na anti- HAV protitelesa in protitelesa proti hepatitisu B po dajanju cepiva Twinrix za odrasle v standardni shemi (0 - 1- 6) v primerjavi s seropozitivnostjo in stopnjo serumske zaščite po monovalentnih cepivih hepatitisa A in B po dajanju v nasprotno roko.
The seroprotection rate against hepatitis B after the administration of Twinrix Adult was 92% and 87.5% at 7 and 12 months respectively, versus 80% and 74% after the GlaxoSmithKline Biologicals monovalent 20µg hepatitis B vaccine, and 71% and 56% after another licensed monovalent 10µg hepatitis B vaccine.
Stopnja serumske zaščite proti hepatitisu B po dajanju cepiva Twinrix za odrasle je bila 92% po 7 mesecih in 87, 5% po 12 mesecih, po dajanju monovalentnega 20 µg cepiva proti hepatitisu B izdelovalca GlaxoSmithKline Biologicals pa 80 in 74% (po 7 in po 12 mesecih) ter 71 in 56% po dajanju nekega drugega registriranega monovalentnega 10 µg cepiva proti hepatitisu B.